Novavax has developed a platform upon which we can manufacture a variety of proprietary recombinant nanoparticle vaccines.
Novavax clinical pipeline includes vaccine candidates engineered to elicit differentiated immune responses with potential to provide increased protection.
Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax has been named a Washington Post Top Workplace for two years running.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources